CureVac N.V. (ETR:5CV)
4.718
+0.002 (0.04%)
Aug 15, 2025, 5:35 PM CET
CureVac Revenue
CureVac had revenue of 1.25M EUR in the quarter ending June 30, 2025, a decrease of -91.38%. This brings the company's revenue in the last twelve months to 510.51M, up 675.15% year-over-year. In the year 2024, CureVac had annual revenue of 535.18M with 895.54% growth.
Revenue (ttm)
510.51M
Revenue Growth
+675.15%
P/S Ratio
2.06
Revenue / Employee
564.72K
Employees
983
Market Cap
1.05B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 23.38B |
Merck KGaA | 21.22B |
Bayer Aktiengesellschaft | 46.17B |
Fresenius SE & Co. KGaA | 22.28B |
Fresenius Medical Care AG | 19.52B |
Sartorius Aktiengesellschaft | 3.47B |
Fielmann Group AG | 2.33B |
Carl Zeiss Meditec AG | 2.18B |
CureVac News
- 1 day ago - CureVac BV reports Q2 results - Seeking Alpha
- 1 day ago - CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates - Wallstreet:Online
- 1 day ago - CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates - Accesswire
- 1 day ago - CureVac's 2025 Mid-Year Financial Surge & Key Business Insights - Wallstreet:Online
- 1 day ago - EQS-News: CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates - Wallstreet:Online
- 8 days ago - GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled - Seeking Alpha
- 8 days ago - GSK to be paid up to £370 million after patent row settles in US - Evening Standard
- 8 days ago - CureVac settles patent dispute litigation with Pfizer and BioNTech - Reuters